Related Experiment Videos
[Aromatase inhibitors: pharmacological aspects]
1Laboratoire de physiopathologie et de pharmacologie, Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05, France.
Abstract:
Selective new aromatase inhibitors are a new class of agents that are of considerable interest in the treatment of hormone-dependent breast cancer in postmenopausal women. Aromatase is an enzymic complex that catalyses the conversion of the adrenal androgens androstenedione and testosterone to estrone. In postmenopausal women, the process of peripheral aromatisation accounts for the majority of circulating estrogens. The selective inhibition of estrogen production by aromatase inhibitors is an efficient strategy for breast cancer treatment. These compounds are classified as irreversible inhibitors of aromatase (type I), and comprise steroidal compounds. Reversible inhibitors of aromatase, which comprises non-steroidal compounds are type II aromatase inhibitors. Second and third generation aromatase inhibitors are considerably more potent and more specific in their ability to inhibit aromatase, as compared with first generation compounds (aminoglutethimide).
Insights
Selective aromatase inhibitors offer a promising treatment for hormone-dependent breast cancer in postmenopausal women by blocking estrogen production. Newer generations are more potent and specific than older ones.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Aromatase inhibitors are crucial for treating hormone-dependent breast cancer in postmenopausal women.
- Aromatase enzymes convert androgens to estrogens, with peripheral aromatization being the primary source of estrogens in postmenopausal women.
- Selective inhibition of estrogen production via aromatase inhibitors is an effective therapeutic strategy.
Purpose of the Study:
- To review the role and advancements in selective aromatase inhibitors for breast cancer treatment.
- To differentiate between steroidal (Type I) and non-steroidal (Type II) aromatase inhibitors.
- To highlight the increased potency and specificity of second and third-generation aromatase inhibitors.
Main Methods:
- Review of scientific literature on aromatase inhibitors.
- Classification of aromatase inhibitors into Type I (irreversible, steroidal) and Type II (reversible, non-steroidal).
- Comparison of the efficacy and specificity of different generations of aromatase inhibitors.
Main Results:
- Selective aromatase inhibition is a key strategy in treating estrogen-dependent breast cancer.
- Aromatase inhibitors are categorized into steroidal (Type I) and non-steroidal (Type II) compounds.
- Second and third-generation aromatase inhibitors demonstrate significantly higher potency and specificity compared to first-generation agents like aminoglutethimide.
Conclusions:
- Selective aromatase inhibitors represent a significant advancement in breast cancer therapy.
- The development of more potent and specific inhibitors (second and third generation) has improved treatment outcomes.
- Aromatase inhibitors provide a targeted approach to reducing estrogen levels in postmenopausal women with breast cancer.